Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Patients treated with coronary drug-eluting stents (n=4154). Intervention: Clopidogrel discontinuation within the first 3 months vs. Continued clopidogrel treatment. Primary outcome: Major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, or definite stent thrombosis) (HR 2.06, 95% CI 1.08-3.93).

Troels Thim; Martin Berg Johansen; Gro Egholm Chisholm; Morten Schmidt; Anne Kaltoft; Henrik Toft Sørensen; Leif Thuesen; Steen Dalby Kristensen; Hans Erik Bøtker; Lars Romer Krusell; Jens Flensted Lassen; Per Thayssen; Lisette Okkels Jensen; Hans–Henrik Tilsted; Michael Mæng

doi:10.1186/1471-2261-14-100

August 13, 2014BMC Cardiovascular DisordersOpen Access

Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

View Full Paper

Ask AI

Bookmark

Share

Key result

Discontinuation of clopidogrel within the first 3 months after drug-eluting stent implantation was associated with a significantly increased rate of MACE at 1-year follow-up (HR 2.06).

Why the study?

Does discontinuation of clopidogrel within the first year after coronary drug-eluting stent implantation increase the risk of major adverse cardiovascular events?

Key Points

To evaluate the impact of clopidogrel discontinuation at different time points within the first year on adverse cardiovascular events after coronary drug-eluting stent implantation.
Followed an observational cohort of 4,154 patients treated with coronary drug-eluting stents in Western Denmark for 1 year.
Identified redeemed clopidogrel prescriptions and major adverse cardiovascular events (cardiac death, myocardial infarction, or stent thrombosis) through Danish medical databases.
Discontinuation within the first 3 months after implantation was associated with a significantly higher 1-year MACE rate (HR 2.06; 95% CI: 1.08–3.93).
Discontinuation between 3–6 months (HR 1.29; 95% CI: 0.70–2.41) and 6–12 months (HR 1.29; 95% CI: 0.54–3.07) showed non-significant increases in MACE.
Among patients who stopped clopidogrel, event rates peaked within the first 2 months following discontinuation.

Study Design

Type

Observational (n=4,154)

Multicenter

Yes

Structured PICO

Does discontinuation of clopidogrel within the first year after coronary drug-eluting stent implantation increase the risk of major adverse cardiovascular events?

P

Population

4,154 patients treated with first-generation coronary drug-eluting stents (sirolimus-eluting or paclitaxel-eluting) in Western Denmark. Key inclusion: first PCI procedure with implantation of one or more coronary DES. Key exclusion: treated with balloon angioplasty without stenting or with bare metal stents alone.

I

Intervention

Discontinuation of clopidogrel (defined as a gap between prescription redemptions of more than 14 days) within the first year after PCI, specifically analyzed at 0-3 months, 3-6 months, and 6-12 months.

C

Comparator

Continued use of clopidogrel (no gap >14 days between prescription redemptions) during the corresponding time periods.

O

Outcome

Major adverse cardiovascular events (MACE), defined as the first occurrence of cardiac death, myocardial infarction, or definite stent thrombosis at 12 months follow-up, adjudicated by a blinded committee of cardiac specialists.composite

Main Result

Effect estimate: HR 2.06 (95% CI 1.08-3.93)

Discontinuation of clopidogrel within the first 3 months after first-generation drug-eluting stent implantation is associated with a significantly increased risk of major adverse cardiovascular events, highlighting the critical importance of early adherence to dual antiplatelet therapy.

Limitations

Patients may have redeemed prescriptions without taking the tablets
Temporary discontinuations of less than 14 days were not detected
Aspirin use could not be completely assessed as it is available without a prescription
Cannot exclude residual confounding despite adjustment for comorbidities
The positive effect of compliance may be lower than estimated from observational studies
Decline in adherence was likely a combination of medical decisions and lack of patient compliance
Results are limited to first-generation drug-eluting stents
Patients may have redeemed prescriptions without taking all or any of the tablets
Temporary discontinuations < 14 days were not detected
Residual confounding cannot be excluded despite adjustment for comorbidities
The true protective effect of clopidogrel in routine clinical care may be lower than estimated from observational studies
Decline in adherence was likely caused by a combination of medical decisions and lack of compliance

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Early clopidogrel discontinuation after DES may raise MACE risk; hypothesis-generating for DAPT duration, needing randomized confirmation.

Abstract

BACKGROUND: The impact of adherence to the recommended duration of dual antiplatelet therapy after first generation drug-eluting stent implantation is difficult to assess in real-world settings and limited data are available. METHODS: We followed 4,154 patients treated with coronary drug-eluting stents in Western Denmark for 1 year and obtained data on redeemed clopidogrel prescriptions and major adverse cardiovascular events (MACE, i.e., cardiac death, myocardial infarction, or stent thrombosis) from medical databases. RESULTS: Discontinuation of clopidogrel within the first 3 months after stent implantation was associated with a significantly increased rate of MACE at 1-year follow-up (hazard ratio (HR) 2.06; 95% confidence interval (CI): 1.08-3.93). Discontinuation 3-6 months (HR 1.29; 95% CI: 0.70-2.41) and 6-12 months (HR 1.29; 95% CI: 0.54-3.07) after stent implantation were associated with smaller, not statistically significant, increases in MACE rates. Among patients who discontinued clopidogrel, MACE rates were highest within the first 2 months after discontinuation. CONCLUSIONS: Discontinuation of clopidogrel was associated with an increased rate of MACE among patients treated with drug-eluting stents. The increase was statistically significant within the first 3 months after drug-eluting stent implantation but not after 3 to 12 months.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thim et al. (2014) conducted an observational in Patients treated with coronary drug-eluting stents (n=4,154). Clopidogrel discontinuation within the first 3 months vs. Continued clopidogrel treatment was evaluated on Major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, or definite stent thrombosis) (HR 2.06, 95% CI 1.08-3.93). Discontinuation of clopidogrel within the first 3 months after drug-eluting stent implantation was associated with a significantly increased rate of MACE at 1-year follow-up (HR 2.06).

synapsesocial.com/papers/6a12bf67b761793c20c07a4a https://doi.org/10.1186/1471-2261-14-100

View Full Paper

Ask AI

Bookmark

Share

Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading